A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
HIV InfectionInfection, Human Immunodeficiency Virus
Interventions
DRUG

Half-boosted Fosamprenavir

Once daily, reduced dose ritonavir-boosted fosamprenavir

DRUG

Full Boosted Fosamprenavir

Full ritonavir-boosted fosamprenavir

Trial Locations (51)

10011

GSK Investigational Site, New York

10595

GSK Investigational Site, Valhalla

18102

GSK Investigational Site, Allentown

20037

GSK Investigational Site, Washington D.C.

21201

GSK Investigational Site, Baltimore

23666

GSK Investigational Site, Hampton

29203

GSK Investigational Site, Columbia

30339

GSK Investigational Site, Atlanta

31201

GSK Investigational Site, Macon

32804

GSK Investigational Site, Orlando

33020

GSK Investigational Site, Hollywood

33136

GSK Investigational Site, Miami

33308

GSK Investigational Site, Fort Lauderdale

33316

GSK Investigational Site, Fort Lauderdale

33334

GSK Investigational Site, Oakland Park

33408

GSK Investigational Site, West Palm Beach

33614

GSK Investigational Site, Tampa

33901

GSK Investigational Site, Fort Myers

34243

GSK Investigational Site, Sarasota

44304

GSK Investigational Site, Akron

46280

GSK Investigational Site, Indianapolis

48202

GSK Investigational Site, Detroit

48910

GSK Investigational Site, Lansing

60153

GSK Investigational Site, Maywood

60612

GSK Investigational Site, Chicago

60613

GSK Investigational Site, Chicago

60657

GSK Investigational Site, Chicago

72207

GSK Investigational Site, Little Rock

75204

GSK Investigational Site, Dallas

75246

GSK Investigational Site, Dallas

76104

GSK Investigational Site, Fort Worth

77027

GSK Investigational Site, Houston

77030

GSK Investigational Site, Houston

78550

GSK Investigational Site, Harlingen

80220

GSK Investigational Site, Denver

85006

GSK Investigational Site, Phoenix

90022

GSK Investigational Site, Los Angeles

90069

GSK Investigational Site, West Hollywood

90211

GSK Investigational Site, Beverly Hills

91356

GSK Investigational Site, Tarzana

92663

GSK Investigational Site, Newport Beach

92708

GSK Investigational Site, Fountain Valley

92845

GSK Investigational Site, Garden Grove

99204

GSK Investigational Site, Spokane

21229-5299

GSK Investigational Site, Baltimore

01103

GSK Investigational Site, Springfield

01107

GSK Investigational Site, Springfield

08844

GSK Investigational Site, Hillsborough

08244

GSK Investigational Site, Somers Point

00731

GSK Investigational Site, Ponce

00909-1711

GSK Investigational Site, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00363142 - A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects | Biotech Hunter | Biotech Hunter